SREBF2 and Huntington disease: The nuclear level and activity of the N-terminal active fragment of SREBP2 are reduced in HD cellular models and mouse brains, and Srebp2 gene therapy in striatal astrocytes alleviates HD phenotypes in R6/2 mice [31].